BRAF V600E
Gene: BRAF · Type: mutation
Indications: Melanoma, Non-small cell lung cancer, Colorectal cancer, Thyroid cancer
Linked CIViC Profile: BRAF V600E
Evidence Level Distribution
Level A: 5Level B: 61Level C: 17Level D: 12
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Diagnostic | Supports | Positive | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib,Dabrafenib | 5 |
| B | Prognostic | Does Not Support | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 5 | |
| B | Prognostic | Supports | Poor Outcome | Papillary Thyroid Carcinoma | 5 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 5 |
| A | Predictive | Supports | Sensitivity/Response | Skin Melanoma | Vemurafenib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Dabrafenib,Trametinib | 5 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Binimetinib,Cetuximab | 5 |
| A | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Encorafenib,Cetuximab | 5 |
| B | Predictive | Does Not Support | Resistance | Colorectal Cancer | Cetuximab,Panitumumab | 4 |
| B | Diagnostic | Supports | Positive | Hairy Cell Leukemia | 4 | |
| B | Predictive | Does Not Support | Sensitivity/Response | Colorectal Cancer | Vemurafenib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib,Cobimetinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Vemurafenib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib,Irinotecan,Cetuximab | 4 |
| B | Prognostic | Supports | Poor Outcome | Colorectal Cancer | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Melanoma | Trametinib | 4 |